Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma
Efficacy and Safety of Neoadjuvant Chemotherapy With Dose Dense MVAC Followed by Radical Surgery in Patients With MIBC and Locally Advanced Urothelial Carcinoma of Bladder: Phase II, Single-arm Study
Sponsor: Pusan National University Yangsan Hospital
This PHASE2 trial investigates Muscle Invasive Bladder Cancer and Neoadjuvant Chemotherapy and is currently ongoing. Pusan National University Yangsan Hospital leads this study, which shows 9 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Mar 2024 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Mar 2022 — Mar 2024 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Oct 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Sep 2019 — Sep 2020 [monthly]
Recruiting PHASE2
First recorded
May 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pusan National University Yangsan Hospital
For direct contact, visit the study record on ClinicalTrials.gov .